You are here: Industry Insights > Public Offering

News List

Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares firstwordpharma
December 25, 2019
The Company has granted to affiliates of GPP the right to nominate two Board members to Abeona's Board of Directors, including a new Executive Chairman, due to GPP's considerable investment in the transaction.
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares firstwordpharma
March 12, 2019
Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering. Cantor Fitzgerald & Co. acted as lead manager for the offering.
Bellerophon Announces Closing of $7 Million Public Offering of Common Stock firstwordpharma
January 28, 2019
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common s
Bellerophon Announces Closing of $7 Million Public Offering of Common Stock firstwordpharma
January 28, 2019
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common s
Orchard Therapeutics Announces Pricing of Initial Public Offering b3cnewswire
November 10, 2018
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering, and Wedbush PacGrow is acting as co-manager.
Adaptimmune Therapeutics Proposes Public Offering of American Depositary Shares firstwordpharma
March 22, 2017
Citigroup, Cowen and Company and Leerink Partners are acting as joint book-running managers for the offering.
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants firstwordpharma
February 14, 2017
Galena Biopharma, Inc. announced the closing of its previously announced underwritten public offering of 17,000,000 shares of common stock and warrants to purchase 17,000,000 shares of common stock priced at $1.00 per share and accompanying warrant.
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants firstwordpharma
February 09, 2017
Galena Biopharma, Inc. today announced the pricing of an underwritten public offering of units with anticipated gross proceeds of $17,000,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.
Ocular Therapeutix Announces Pricing of Public Offering of Common Stock firstwordpharma
January 25, 2017
Ocular Therapeutix, Inc. announced today the pricing of a registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.00 per share...
Stemline Therapeutics Prices $45 Million Public Offering of Common Stock firstwordpharma
January 23, 2017
Stemline Therapeutics, Inc. (Nasdaq:STML) announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, with expected gross proceeds to Stemline of $45 million.

Previous page 1 2 Next page